Payment overview · 2025
General Payments
$339.45
16 reported records · 8 companies
Healthcare provider profile · identity verified
Muzafar H Surahio, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · STATEN ISLAND, NY · NPI 1932141017
Verified facts
What the public records show
CMS Open Payments records show Muzafar H Surahio, MD received $339.45 in general payments during 2025 across 16 reported records.
Janssen Biotech, Inc. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $77.58 | 22.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.02 | 21.8% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $53.55 | 15.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.50 | 11.9% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.96 | 10.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.22 | 6.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.84 | 6.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.78 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.45 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $77.58 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $74.02 | 4 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $53.55 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $40.50 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $34.96 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 650 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 444 | 95 |
| Losartan Potassium | Losartan Potassium | 393 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 355 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 324 | 69 |
| Metformin Hcl | Metformin Hcl | 309 | 65 |
| Gabapentin | Gabapentin | 224 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 189 | 35 |
| Omeprazole | Omeprazole | 188 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 26 |
| Nifedipine Er | Nifedipine | 160 | 29 |
| Lisinopril | Lisinopril | 146 | 28 |
| Simvastatin | Simvastatin | 146 | 25 |
| Famotidine | Famotidine | 141 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 25 |
| Furosemide | Furosemide | 112 | 22 |
| Atenolol | Atenolol | 106 | 14 |
| Enalapril Maleate | Enalapril Maleate | 91 | 14 |
| Eliquis | Apixaban | 88 | 16 |
| Meloxicam | Meloxicam | 78 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 12 |
| Montelukast Sodium | Montelukast Sodium | 66 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 64 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | 11 |
| Carvedilol | Carvedilol | 57 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 19 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 54 | suppressed |
| Chlorthalidone | Chlorthalidone | 51 | 11 |
| Ibuprofen | Ibuprofen | 50 | 16 |
| Labetalol Hcl | Labetalol Hcl | 49 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 48 | 17 |
| Glipizide Er | Glipizide | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 13 |
| Naproxen | Naproxen | 40 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 13 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Procto-Med Hc | Hydrocortisone | 31 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Rifampin | Rifampin | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $339.45 · 16 records | Janssen Biotech, Inc. | ABRYSVO, AMVUTTRA, AUSTEDO XR, BREZTRI, COMIRNATY, GVOKE HYPOPEN, Omnipod, PREVNAR 20, TREMFYA, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error